Evidence map›Paper›PMID 20464462›Full record

ArticlePharmaceutical research2010

Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial.

Biswanath Kundu, Chidambaram Soundrapandian, Samit K Nandi, Prasenjit Mukherjee, Nandadulal Dandapat, Subhasis Roy, Bakul K Datta, Tapan K Mandal, Debabrata Basu, Rupnarayan N Bhattacharya

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. Biodegradable composites with antibiotics and growth factors for dual release kinetics.Journal of materials science. Materials in medicine · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Silver nanoparticle deposited implants to treat osteomyelitis.Journal of biomedical materials research. Part B, Applied biomaterials · 2018
    Article
  14. Article
  15. Protein-Based Drug-Delivery Materials.Materials (Basel, Switzerland) · 2017
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Biswanath KunduBioceramics and Coating Division, Central Glass and Ceramic Research Institute, Kolkata, India. biswa_kundu@rediffmail.com
Chidambaram Soundrapandian
Samit K Nandi
Prasenjit Mukherjee
Nandadulal Dandapat
Subhasis Roy
Bakul K Datta
Tapan K Mandal
Debabrata Basu
Rupnarayan N Bhattacharya
West Bengal University of Animal and Fishery Sciences · INCentral Glass and Ceramic Research Institute · INR. G. Kar Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePresent investigation deals with an extensive approach incorporating in vitro and in vivo experimentation to treat chronic osteomyelitis, using hydroxyapatite porous scaffolds. MATERIALS AND

methodsHydroxyapatite was synthesized in the laboratory by wet chemical method, different porous scaffolds have been fabricated. In vitro studies include variation of porosity with interconnectivity, pore-drug interfacial studies by SEM-EDAX and drug elution studies (by HPLC) both in contact with PBS and SBF at approximately 37 degrees C. In vivo trials were based on experimental osteomyelitis in rabbit model induced in tibia by Staphylococcus aureus. Characterizations included observation of histopathology, radiology and estimation of drug in both bone and serum for 42 days by HPLC method and subsequent bone-biomaterial interface by SEM.

resultsIt was established that lower pore percentage with a distribution of mainly micro-pores were found to be superior over the higher pore percentage both in vitro and in vivo. The criteria was matched with the 50N50H samples which had 50-55% porosity with an average pore size approximately 110 microm, having higher interconnectivity (10-100 microm), moderately high adsorption efficiency (approximately 50%) when loaded with CFS (drug combinations consisting of irreversible b-lactamase inhibitor and b-lactam antibiotic). CFS release from HAp implants were faster in PBS than SBF. Further, both the results of in vitro and in vivo drug elution after 42 days showed release higher than minimum inhibitory concentration of CFS against Staphylococcus aureus. In vivo studies also proved the superiority of CFS loaded HAp implants than parenteral group based on eradication of infection and new bone formation.

conclusionsHAp based porous scaffold loaded with CFS and designed porosity (in terms of micro- and macro-porosity, interconnectivity) was found to be an ideal delivery system which could locally, sustainably release the composite antibiotic in reliable manner both in terms of in vitro drug elution behaviour in contact with SBF and in vivo animal trial.

Indexed as

Disease Models, AnimalDrug Delivery SystemsAnimalsAnti-Bacterial AgentsCeftriaxoneDrug CompoundingDurapatiteHydrogen-Ion ConcentrationMicroscopy, Electron, ScanningOsteomyelitisPorosityPowdersRabbitsStaphylococcus aureusSulbactamX-Ray DiffractionAnti-Bacterial AgentsCeftriaxoneDurapatitePowdersSulbactam

Identifiers

PMID20464462
OpenAlexW2033391607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.